Hypoxia Inducible Factor 1 Alpha - Pipeline Review, H2 2017

  • ID: 4426906
  • Report
  • 77 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • CASI Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • NewLink Genetics Corp
  • OncoImmune Inc
  • Peloton Therapeutics Inc
  • RXi Pharmaceuticals Corp
  • MORE
Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Pipeline Review, H2 2017

Summary

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) pipeline Target constitutes close to 15 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Hypoxia Inducible Factor 1 Alpha - Pipeline Review, H2 2017, outlays comprehensive information on the Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Hypoxia-inducible factor 1-alpha is a subunit of a heterodimeric transcription factor encoded by the HIF1A gene. It plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. It activates the transcription of erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor and HILPDA under hypoxia condition. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1, 4 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular, Central Nervous System, Dermatology, Metabolic Disorders and Ophthalmology which include indications Lung Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Diabetic Foot Ulcers, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Hepatocellular Carcinoma, Ischemia, Kidney Cancer (Renal Cell Cancer), Melanoma, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Non-Small Cell Lung Cancer, Pancreatic Cancer, Peritoneal Cancer, Rectal Cancer, Rheumatoid Arthritis, Small-Cell Lung Cancer and Wounds.

Furthermore, this report also reviews key players involved in Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A)
  • The report reviews Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics.
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • CASI Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • NewLink Genetics Corp
  • OncoImmune Inc
  • Peloton Therapeutics Inc
  • RXi Pharmaceuticals Corp
  • MORE
Introduction

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Overview

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Companies Involved in Therapeutics Development

CASI Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Ildong Pharmaceutical Co Ltd

NewLink Genetics Corp

OncoImmune Inc

Peloton Therapeutics Inc

RXi Pharmaceuticals Corp

Sorrento Therapeutics Inc

Vascular Biogenics Ltd

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Drug Profiles

A-503451A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide to Inhibit HIF-1 Alpha for Retinal Disease and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BC-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CASI-2ME2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRLX-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Echinomycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HS-1793 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDF-11774 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KCN-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MPT-0B098 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit HIF-1 Alpha for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-16388 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TR-764 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-411 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Dormant Products

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Discontinued Products

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Product Development Milestones

Featured News & Press Releases

Oct 06, 2016: Cerulean Announces Clinical Data from CRLX101 Program at the 2016 European Society for Medical Oncology Annual Meeting

Aug 18, 2016: Cerulean Announces Reduction in Force

Aug 18, 2016: Cerulean Announces Results from Phase 2 Clinical Trial of CRLX101 and Avastin Combination in Relapsed Renal Cell Carcinoma

Jul 19, 2016: Cerulean Receives FDA Fast Track Designation for CRLX101 for the Treatment of Platinum-Resistant Ovarian Cancer

Jun 22, 2016: Cerulean Announces Publication in Cancer Research

Jun 09, 2016: Cerulean Announces Manuscript Published in Annals of Oncology

May 19, 2016: Cerulean Announces Oral Presentation on Phase 1b results of CRLX101 at Gynecologic Oncology 2016 Conference

May 10, 2016: Cerulean Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRLX101 in Combination with LYNPARZA

Apr 25, 2016: Cerulean Announces Oral Presentation of CRLX101 Clinical Data at Gynecologic Oncology 2016 Conference

Apr 19, 2016: Cerulean Announces Presentation at 2016 American Association for Cancer Research Annual Meeting of Stage 1 Data from Phase 2 Trial in Platinum-Resistant Ovarian Cancer

Mar 23, 2016: Cerulean Announces Publication Showing CRLX101 Localizes Selectively in Human Tumors, Sparing Adjacent Healthy Tissue

Mar 16, 2016: Cerulean Announces Data Presentation at the 2016 American Association for Cancer Research Annual Meeting

Nov 09, 2015: Cerulean Announces Data at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 27, 2015: Cerulean Announces Poster Presentations at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 19, 2015: Cerulean Announces First Patient Dosed in Clinical Trial to Evaluate Weekly Dosing Schedule with CRLX101

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by CASI Pharmaceuticals Inc, H2 2017

Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Pipeline by Ildong Pharmaceutical Co Ltd, H2 2017

Pipeline by NewLink Genetics Corp, H2 2017

Pipeline by OncoImmune Inc, H2 2017

Pipeline by Peloton Therapeutics Inc, H2 2017

Pipeline by RXi Pharmaceuticals Corp, H2 2017

Pipeline by Sorrento Therapeutics Inc, H2 2017

Pipeline by Vascular Biogenics Ltd, H2 2017

Dormant Products, H2 2017

Discontinued Products, H2 2017

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • CASI Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • Ildong Pharmaceutical Co Ltd
  • NewLink Genetics Corp
  • OncoImmune Inc
  • Peloton Therapeutics Inc
  • RXi Pharmaceuticals Corp
  • Sorrento Therapeutics Inc
  • Vascular Biogenics Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll